On August 7, 2025, C4 Therapeutics, Inc. reported its financial results and updates from its Phase 1 clinical trial of cemsidomide, showing a promising 40% overall response rate for multiple myeloma at a specific dosage. The company also plans to align with the FDA for further development by early 2026.